Valneva (EURONEXT:VLA), (NASDAQ:VALN) is a specialty vaccine company focused on the development, production, and commercialization of innovative vaccines for infectious diseases with significant unmet medical need. Its projects span Lyme disease, the chikungunya virus, and COVID-19, demonstrating a diversified and forward-thinking approach to global health challenges. Valneva aims to leverage its deep understanding of vaccine technology to protect people from these threats, underscoring its commitment to public health and safety. The company also prioritizes strategic partnerships and licensing agreements to enhance its vaccine portfolio and expand its reach. With a direct presence in Europe, the United States, and Asia, Valneva is dedicated to becoming a key player in the vaccine industry by delivering high-quality, life-saving vaccines across the globe.